Table 3 Associations between nivolumab and miRNAs in different cancer types
Cancer type | miRNA | Expression levels | Association with nivolumab response |
|---|---|---|---|
NSCLC | miR-200c, miR-34a | Increased | Response and outcome |
miR-320, miR-375 | Decreased | Positive clinical outcomes, decrease in immunosuppressive cytokines | |
RCC | miR-339 | Decreased | Weakened immune response against tumors; progression-free survival (PFS) |
Metastatic melanoma | miR-155 | Increased | Overall survival; decreased levels of PTPN2 |